Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
A bidding war has netted Sarepta the largest-ever licensing deal for a cell or gene therapy. Can Roche make it work?
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.